Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate

Dow Jones

Mar 26

By Elias Schisgall

Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne

The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year.

The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024.

Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue.

Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million.

Write to Elias Schisgall at elias.schisgall@wsj.com

(END) Dow Jones Newswires

March 25, 2026 18:09 ET (22:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/2622000415"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622000415\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622000415?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 06:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622000415","market":"us","top_or_hot":-1,"title":"Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n</p>\n<p>\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n</p>\n<p>\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n</p>\n<p>\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n</p>\n<p>\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Journey Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJourney Medical Shares Retreat After Annual Revenue Misses Wall Street's Estimate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-26 06:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Elias Schisgall \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n</p>\n<p>\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n</p>\n<p>\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n</p>\n<p>\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n</p>\n<p>\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 25, 2026 18:09 ET (22:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DERM","symbol_name":"Journey Medical Corp","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2622000415","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622000415","pubTimestamp":1774476540,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne. The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year.The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024.Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue.Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"DERM":"Journey Medical Corp"},"translate_title":"年收入低于华尔街预期后，Journey Medical股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DERM":1.5},"content_text":"By Elias Schisgall \n\n\n \n\n\n  Shares of Journey Medical fell after the company reported 2025 revenue that missed Wall Street's expectations due to falling sales for Accutane, treatment for severe cases of acne \n\n\n  The stock was down 7.7% to $6.30 in post-market trading on Wednesday, falling deeper into negative territory after closing the regular trading session off by 1.2%. Shares are up 5.4% in the past year. \n\n\n  The commercial-stage pharmaceutical company reported a full-year loss of $11.4 million, or 47 cents a share, compared with a loss of $14.7 million, or 72 cents a share, in 2024. \n\n\n  Revenue rose to $61.9 million, up from $56.1 million in 2024. Analysts polled by FactSet were expecting $64.6 million in revenue. \n\n\n  Growth in revenue was driven by inaugural sales for and the commercialization of Emrosi. That was offset by competitive pressures on Accutane revenue, which fell by $6.5 million. \n\n\n \n\n\n  Write to Elias Schisgall at elias.schisgall@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 25, 2026 18:09 ET (22:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}